Cadrenal Therapeutics, Inc.

CVKD

US1276361086

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:22:59 2024-05-23 pm EDT			5-day change	1st Jan Change
0.415 ^USD	+0.56%		-3.49%	-43.90%

May. 09	Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	CI

Cadrenal Therapeutics, Inc. has completed an IPO in the amount of $7 million.

January 20, 2023 at 12:00 am EST

Cadrenal Therapeutics, Inc. has completed an IPO in the amount of $7 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,400,000
PriceRange: $5
Discount Per Security: $0.35

Latest news about Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	Apr. 09	CI
Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin	Apr. 09	DJ
Cadrenal Therapeutics Files $100 Million Mixed Shelf; Shares Fall	Mar. 12	MT
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer	Feb. 08	CI
Certain Warrants of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	Jan. 19	CI
Certain Common Stock of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	Jan. 19	CI
Certain Stock Options of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	Jan. 19	CI
Noble Capital Starts Cadrenal Therapeutics With Outperform Rating, $4 Price Target	Dec. 18	MT
HC Wainwright Initiates Cadrenal Therapeutics With Buy Rating	Nov. 20	MT
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Cadrenal Therapeutics Highlights Additional Need for A New Vitamin K Antagonist Following Updates from the Recent European Society of Cardiology Congress	23-09-05	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Cadrenal Therapeutics, Inc. Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases	23-08-01	CI
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors	23-07-24	CI
Cadrenal Therapeutics Closes $7.5 Million Private Placement	23-07-14	MT
Cadrenal Therapeutics, Inc. announced that it has received $7.500001 million in funding	23-07-13	CI
Cadrenal Therapeutics to Raise $7.5 Million From Share Placement	23-07-12	MT
Top Premarket Gainers	23-07-12	MT
Cadrenal Therapeutics, Inc. announced that it expects to receive $7.500001 million in funding	23-07-11	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Eleven Months Ended December 31, 2022	23-03-30	CI
Cadrenal Therapeutics, Inc.(NasdaqCM:CVKD) added to S&P TMI Index	23-03-20	CI
Cadrenal Therapeutics, Inc. Announces Board Appointments	23-02-01	CI

Chart Cadrenal Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Companyâs lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Lytham Partners Spring Investor Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4127 USD

Average target price

3.5 USD

Spread / Average Target

+748.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CADRENAL THERAPEUTICS, INC.	-43.90%	6.61M
ELI LILLY AND COMPANY	+39.57%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.08%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.86%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.36%	168B

Other Pharmaceuticals